Skip to main content
Publications
Germing U, Goyal RK, Yucel A, Parikh RC, Jimenez M, Sluga-O'Callaghan M, Tang D, Hughes C, Diez-Campelo M. Real-world evidence on treatment utilization in lower-risk myelodysplastic syndromes: findings from a medical record review in the United States. Poster presented at the 63rd ASH Annual Meeting and Exposition; December 11, 2021. Atlanta, GA. [abstract] Blood. 2021 Nov 23; 138(Suppl 1):4666. doi: 10.1182/blood-2021-145576
Kabadi SM, Goyal RK, Nagar SP, Davis KL, Le H, Du XL, Jain P, Wang ML, Romaguera JE, Kaye JA. Overall survival, adverse events, and economic burden in Medicare-insured patients with mantle cell lymphoma receiving cancer-directed therapy. Presented at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition; December 7, 2019. Orlando, FL. [abstract] Blood. 2019 Nov 13; 134(Supplement_1):63. doi: 10.1182/blood-2019-122841
Adrianzen Herrera D, Pradhan K, Snyder R, Karanth S, Janakiram M, Mantzaris I, Murthy S, Verma A, Shastri A. Myelodysplastic Syndromes (MDS) are an independent risk factor for an earlier onset of myocardial infarction and increased mortality from Cardiovascular Disease (CVD). Poster presented at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition; November 29, 2018. San Diego, CA. [abstract] Blood. 2018; 132(Suppl 1):3539. doi: 10.1182/blood-2018-99-115613